Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABT-737 + Anti-CD19 CAR-T cells |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABT-737 | ABT737|ABT 737 | BCL-XL inhibitor 14 BCL2 inhibitor 27 | ABT-737 is a BH3 mimetic, which targets Bcl2, Bcl-xl, and Bcl-w to induce apoptosis (PMID: 32623836). | |
Anti-CD19 CAR-T cells | CD19 Immune Cell Therapy 62 | Anti-CD19 CAR-T cells are T-cells that express a chimeric antigen receptor that targets the CD19 surface protein on B-lymphocytes, which results in anti-tumor activity in B-cell malignancies (PMID: 25999455, PMID: 26425336). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|